AI Engines For more Details: Perplexity Kagi Labs You
Hemostatic Agent: Aminocaproic acid is a synthetic derivative of the amino acid lysine. It works by inhibiting the breakdown of blood clots, specifically by blocking the activation of plasminogen to plasmin, which is an enzyme that degrades fibrin and helps dissolve blood clots. By inhibiting fibrinolysis, aminocaproic acid helps stabilize blood clots and reduce bleeding.
Surgical Use: Aminocaproic acid is commonly used in surgical procedures to control bleeding, particularly in surgeries where there is a risk of excessive bleeding or where fibrinolysis needs to be inhibited to maintain hemostasis. It may be used in various surgical specialties, including cardiac surgery, orthopedic surgery, and urologic surgery.
Trauma and Hemorrhage: Aminocaproic acid may also be used to manage bleeding in traumatic injuries or hemorrhagic conditions, such as disseminated intravascular coagulation (DIC) or obstetric hemorrhage. It can help reduce bleeding and prevent the progression of coagulopathy in these situations.
Hereditary Bleeding Disorders: Aminocaproic acid may be used as adjunctive therapy in the management of certain hereditary bleeding disorders, such as hemophilia or von Willebrand disease. It can help reduce bleeding episodes and improve clot stability in these patients.
Side Effects: Common side effects of aminocaproic acid may include nausea, vomiting, diarrhea, abdominal discomfort, and dizziness. These side effects are usually mild and temporary. However, in rare cases, aminocaproic acid may cause more serious side effects, such as thromboembolic events (e.g., blood clots), particularly in patients with a predisposition to thrombosis or in high-risk surgical procedures.
Renal Impairment: Aminocaproic acid is primarily excreted by the kidneys. Patients with renal impairment may require dosage adjustments or close monitoring during treatment with aminocaproic acid to prevent drug accumulation and potential adverse effects.
Contraindications: Aminocaproic acid is contraindicated in patients with a history of thromboembolic events, such as stroke, myocardial infarction, or pulmonary embolism, unless the potential benefits outweigh the risks. It should be used with caution in patients with conditions predisposing to thrombosis, such as severe hypertension or hypercoagulable states.
Drug Interactions: Aminocaproic acid may interact with certain medications, including anticoagulants, antiplatelet agents, and thrombolytic drugs. Concomitant use of these medications may increase the risk of bleeding or thromboembolic events and should be carefully monitored.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
ADHD | 0.5 | 0.5 | |
Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
Allergic Rhinitis (Hay Fever) | 1 | 1 | |
Allergies | 0.8 | 0.8 | |
Allergy to milk products | 0.5 | 0.6 | -0.2 |
Alopecia (Hair Loss) | 0.9 | 0.9 | |
Alzheimer's disease | 1.6 | 1.6 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.3 | 1.33 |
Ankylosing spondylitis | 1.7 | 0.5 | 2.4 |
Anorexia Nervosa | 0.4 | 0.2 | 1 |
Antiphospholipid syndrome (APS) | 0.6 | 0.5 | 0.2 |
Asthma | 0.2 | -0.2 | |
Atherosclerosis | 0.1 | 0.1 | |
Atrial fibrillation | 0.8 | 1.2 | -0.5 |
Autism | 1.3 | 1.9 | -0.46 |
Barrett esophagus cancer | 0.1 | 0.2 | -1 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.2 | 1.2 | |
Brain Trauma | 0.2 | -0.2 | |
Carcinoma | 1.5 | 0.6 | 1.5 |
Celiac Disease | 0.8 | 1 | -0.25 |
Cerebral Palsy | 0.2 | 0.2 | 0 |
Chronic Fatigue Syndrome | 0.8 | 2 | -1.5 |
Chronic Kidney Disease | 1 | 1 | |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.3 | |
Chronic Urticaria (Hives) | 0.8 | 0.5 | 0.6 |
Coagulation / Micro clot triggering bacteria | 1.2 | 0.2 | 5 |
Colorectal Cancer | 2.2 | 2.2 | |
Constipation | 0.4 | 0.4 | |
Coronary artery disease | 0.2 | 0.2 | |
COVID-19 | 2.1 | 1.1 | 0.91 |
Crohn's Disease | 2.5 | 1.1 | 1.27 |
cystic fibrosis | 0.5 | 0.2 | 1.5 |
deep vein thrombosis | 0.5 | 0.2 | 1.5 |
Depression | 3.8 | 1.7 | 1.24 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.4 | 1.1 | -1.75 |
Endometriosis | 1.3 | 1.3 | |
Eosinophilic Esophagitis | 0.1 | 0.1 | |
Epilepsy | 1.2 | 1.3 | -0.08 |
Fibromyalgia | 1.1 | 0.2 | 4.5 |
Functional constipation / chronic idiopathic constipation | 1.6 | 1 | 0.6 |
gallstone disease (gsd) | 0.6 | 0.1 | 5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.2 | 2 |
Generalized anxiety disorder | 0.8 | 0.2 | 3 |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0.6 | 0.6 | |
Halitosis | 0.3 | 0.2 | 0.5 |
Hashimoto's thyroiditis | 0.2 | 0.6 | -2 |
Hidradenitis Suppurativa | 0.8 | 0.8 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.1 | 4 |
hyperglycemia | 0.2 | 0.6 | -2 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 1 | 1.4 | -0.4 |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 0.2 | -0.2 | |
Inflammatory Bowel Disease | 2 | 1.6 | 0.25 |
Insomnia | 0.4 | 0.2 | 1 |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 1.1 | 0.6 | 0.83 |
Liver Cirrhosis | 1.5 | 0.9 | 0.67 |
Long COVID | 1.6 | 1.1 | 0.45 |
Lung Cancer | 0.5 | 0.5 | |
ME/CFS with IBS | 0.2 | 0.2 | 0 |
ME/CFS without IBS | 0.6 | 1.1 | -0.83 |
Metabolic Syndrome | 2.9 | 1.8 | 0.61 |
Mood Disorders | 4.2 | 1.7 | 1.47 |
multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
Multiple Sclerosis | 2.2 | 2.2 | 0 |
Multiple system atrophy (MSA) | 0.6 | 0.6 | |
Neuropathy (all types) | 0.2 | 0.2 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.2 | 1 |
Obesity | 2 | 1 | 1 |
obsessive-compulsive disorder | 1.8 | 0.4 | 3.5 |
Osteoarthritis | 0.8 | 0.8 | |
Osteoporosis | 0.4 | 0.2 | 1 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 1.4 | 1 | 0.4 |
Polycystic ovary syndrome | 0.8 | 0.8 | |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
Psoriasis | 1.1 | 1.5 | -0.36 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 0.7 | 1.57 |
Schizophrenia | 1 | 1 | |
scoliosis | 0.5 | -0.5 | |
Sjögren syndrome | 0.8 | 0.6 | 0.33 |
Sleep Apnea | 0.1 | 0.2 | -1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
Stress / posttraumatic stress disorder | 1 | 0.2 | 4 |
Systemic Lupus Erythematosus | 2.2 | 2.2 | |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 1.3 | 0.2 | 5.5 |
Type 2 Diabetes | 2.9 | 1.7 | 0.71 |
Ulcerative colitis | 1 | 1 | 0 |
Unhealthy Ageing | 1.8 | 1.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.